Related Experiment Video
Updated: Dec 16, 2025

Modeling Age-Associated Neurodegenerative Diseases in Caenorhabditis elegans
Published on: August 15, 2020
Compounds that extend longevity are protective in neurodegenerative diseases and provide a novel treatment strategy
Sonja K Soo1, Paige D Rudich1, Annika Traa1
1Department of Neurology and Neurosurgery, McGill University, Montreal, QC, H4A 3J1, Canada; Metabolic Disorders and Complications Program, and Brain Repair and Integrative Neuroscience Program, Research Institute of the McGill University Health Centre, Montreal, QC, H4A 3J1, Canada.
Abstract:
While aging is the greatest risk factor for the development of neurodegenerative disease, the role of aging in these diseases is poorly understood. In the inherited forms of these diseases, the disease-causing mutation is present from birth but symptoms appear decades later. This indicates that these mutations are well tolerated in younger individuals but not in older adults. Based on this observation, we hypothesized that changes taking place during normal aging make the cells in the brain (and elsewhere) susceptible to the disease-causing mutations. If so, then delaying some of these age-related changes may be beneficial in the treatment of neurodegenerative disease. In this review, we examine the effects of five compounds that have been shown to extend longevity (metformin, rapamycin, resveratrol, N-acetyl-l-cysteine, curcumin) in four of the most common neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis). While not all investigations observe a beneficial effect of these compounds, there are multiple studies that show a protective effect of each of these lifespan-extending compounds in animal models of neurodegenerative disease. Combined with genetic studies, this suggests the possibility that targeting the aging process may be an effective strategy to treat neurodegenerative disease.
Insights
Aging accelerates neurodegenerative diseases. Targeting aging processes with longevity compounds may offer new treatments for conditions like Alzheimer's and Parkinson's disease.
Area of Science:
- Neuroscience
- Gerontology
- Pharmacology
Background:
- Aging is the primary risk factor for neurodegenerative diseases.
- Inherited neurodegenerative diseases manifest late in life, suggesting age-related cellular changes increase mutation susceptibility.
Purpose of the Study:
- To investigate if targeting aging processes can mitigate neurodegeneration.
- To review lifespan-extending compounds for treating Alzheimer's, Parkinson's, Huntington's, and ALS.
Main Methods:
- Review of existing studies on five longevity compounds: metformin, rapamycin, resveratrol, N-acetyl-l-cysteine, and curcumin.
- Examination of compound effects in animal models of four major neurodegenerative diseases.
Main Results:
- Multiple studies demonstrate protective effects of these compounds in neurodegenerative disease models.
- Not all studies showed beneficial effects, indicating varied compound efficacy.
Conclusions:
- Targeting the aging process presents a potential therapeutic strategy for neurodegenerative diseases.
- Lifespan-extending compounds show promise in preclinical models, warranting further investigation.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Parkinson's Disease: Overview
Long-term Potentiation
Long-term Potentiation
Hebbian LTP
LTP can occur when...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

